Effects of the PPARγ activator pioglitazone on p38 MAP kinase and IκBα in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis

Neuropathology

Volumn 28, Issue 4, 2008, Pages 387-398

  Shibata, Noriyuki ^a   Kawaguchi Niida, Motoko ^a   Yamamoto, Tomoko ^a   Toi, Sono ^b   Hirano, Asao ^c   Kobayashi, Makio ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Amyotrophic lateral sclerosis; Inhibitor of nuclear factor kappaB alpha; p8 mitogen activated protein kinase; Peroxisome proliferator activated receptor gamma; Pioglitazone

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NEURON SPECIFIC NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; AIF1 PROTEIN, MOUSE; ANTIINFLAMMATORY AGENT; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B; NERVE PROTEIN; NEUN PROTEIN, MOUSE; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NUCLEAR PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL POPULATION; CELL PROTECTION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; FEMALE; IMAGE ANALYSIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MOTONEURON; MOUSE; NERVE CELL; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SPINAL CORD; SPINAL CORD VENTRAL HORN; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; IMAGE PROCESSING; METABOLISM; MUTATION; PATHOLOGY; WESTERN BLOTTING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; I-KAPPA B PROTEINS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; SPINAL CORD; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES;

EID: 44849091020     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2008.00890.x     Document Type: Article

References (67)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001 2:806 819.
2. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001 27:257 274.
3. Cluskey S, Ramsden DB. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. J Clin Pathol Mol Pathol 2001 54:386 392.
4. Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995 38:73 84.
5. Van Den Bosch L, Van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006 1762:1068 1082.
6. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002 26:459 470.
7. Consilvio C, Vincent AM, Feldman EL. Neuroinflammation, COX-2, and ALS. Exp Neurol 2004 187:1 10.
8. Carri MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 2003 61:365 374.
9. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004 10 (Suppl S18 S25.
10. Zhao W, Xie W, Le W et al. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanisms. J Neuropathol Exp Neurol 2004 63:964 977.
11. Takeuchi H, Jin S, Wang J et al. Tumor necrosis factor-α induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem 2006 281:21362 21368.
12. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. RNA editing and death of motor neurons. Nature 2004 427:801.
13. Atlante A, Calissano P, Bobba A, Giannattasio S, Marra E, Passarella S. Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett 2001 497:1 5.
14. Shibata N, Nagai R, Uchida K et al. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res 2001 917:97 104.
15. Shibata N, Satoshi Y, Uchida K et al. Accumulation of protein-bound 4-hydroxy-2-hexenal in spinal cords from patients with sporadic amyotrophic lateral sclerosis. Brain Res 2004 1019:170 177.
16. Shibata T, Iio K, Kanai Y et al. Identification of a lipid peroxidation product as a potential trigger of the p53 pathway. J Biol Chem 2006 281:1196 1204.
17. Shibata N, Kawaguchi M, Uchida K et al. Protein-bound crotonaldehyde accumulates in the spinal cord of superoxide dismutase-1 mutation-associated familial amyotrophic lateral sclerosis and its transgenic mouse model. Neuropathology 2007 27:49 61.
18. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007 184:69 91.
19. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007 150:963 976.
20. Combs CK, Johnson DE, Kario JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 2000 20:558 567.
21. Yan Q, Zhang J, Liu H et al. Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 2003 23:7504 7509.
22. Heneka MT, Sastre M, Dumitrescu-Ozimek L et al. Acute treatment with PPARgamma agonist pioglitazone and ibufrofen reduces glial inflammation and Abeta-42 levels in APPV7171 transgenic mice. Brain 2005 128:1442 1453.
23. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002 82:615 624.
24. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schultz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation. J Neurochem 2004 88:494 501.
25. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 2005 191:331 336.
26. Schütz B, Reimann J, Dumitrescu-Ozimek L et al. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-linked symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 2005 25:7805 7812.
27. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 2000 106:467 472.
28. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004 351:1106 1118.
29. Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus 2005 14:794 797.
30. Bernardo A, Minghetti L. PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr Pharmaceut Design 2006 12:93 109.
31. Drew PD, Xu J, Storer PD, Chavis J, Racke MK. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int 2006 49:183 189.
32. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonists improve insulin resistance. J Biol Chem 2001 276:41245 41254.
33. Bruenmmer D, Yin F, Liu J et al. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells. Circ Res 2003 93:e38 47.
34. Bodles AM, Varma V, Yao-Borengasser A et al. Pioglitazone induces apoptosis of macrophages in human adipose tissue. J Lipid Res 2006 47:2080 2088.
35. Liu DC, Zang CB, Liu HY, Possinger K, Fan SG, Elstner E. A novel PPAR α/γ dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin 2004 25:1312 1319.
36. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006 118:773 779.
37. Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist piglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 2007 43:1755 1763.
38. Burton JD, Castillo ME, Goldenberg DM, Blumenthal RD. Peroxisome proliferator-activated receptor-γ antagonists exhibits potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs 2007 18:525 534.
39. Yang Y-C, Tsao Y-P, Ho T-C, Choung I-P. Peroxisome proliferator-activated receptor-γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 2007 17:418 425.
40. Nishijima C, Kimoto K, Arakawa Y. Survival activity of troglitazone in rat motoneurones. J Neurochem 2001 76:383 390.
41. Aoun P, Watson DG, Simpkins JW. Neuroprotective effects of PPARγ agonists against oxidative insults in HT-22 cells. Eur J Pharmacol 2003 472:65 71.
42. Park S-W, Yi J-H, Miranpuri G et al. Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Therapeut 2007 320:1002 1012.
43. Tureyen K, Kapadia R, Bowen KK et al. Peroxisome proliferator-activated receptor-γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007 101:41 56.
44. Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARγ as a therapeutic target in central nervous system diseases. Neurochem Int 2006 49:136 144.
45. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005 15:11 18.
46. Brasier AR. The NF-κB regulatory network. Cardiovasc Toxicol 2006 6:111 130.
47. Tortarolo M, Veglianese P, Calvaresi N et al. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci 2003 23:180 192.
48. Veglianese P, Coco DL, Bao Cutrona M et al. Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci 2006 31:218 231.
49. Raoul C, Buhler E, Sadeghi C et al. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc Natl Acad Sci USA 2006 103:6007 6012.
50. Aoun P, Simpkins JW, Agarwal N. Role of PPAR-γ ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganlion cells. Invest Ophthalmol Vis Sci 2003 44:2999 3004.
51. Chung SW, Kang BY, Kim SH et al. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB. J Biol Chem 2000 275:32681 32687.
52. Hernandez R, Teruel T, De Alvaro C, Lorenzo M. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wister rats by impairing TNF-α induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 2004 47:1615 1624.
53. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006 291:H1738 H1745.
54. Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994 264:1772 1775.
55. Sapan CV, Lundblad RL, Price NC. Colorimetric protein assay techniques. Biotechnol Appl Biochem 1999 29:99 108.
56. Chaparro-Huerta V, Rivera-Cervantes MC, Flores-Soto ME, Gómez-Pinedo U, Beas-Zárate C. Proinflammatory cytokines and apoptosis following glutamate-induced excitotoxicity mediated by p38 MAPK in the hippocampus of neonatal rats. J Neuroimmunol 2005 165:53 62.
57. Segura Torres JE, Chaparro-Huerta V, Rivera Cervantres MC, Montes-González R, Flores Soto ME, Beas-Zárate C. Neuronal cell death due to glutamate excitotoxicity is mediated by P38 activation in the rat cerebral cortex. Neurosci Lett 2006 403:233 238.
58. G93A- induced motor neuron death. Neurobiol Dis 2007 26:332 341.
59. Guo G, Bhat NR. p38α MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem Res 2007 32:2160 2166.
60. Xu Z, Wang B-R, Wang X et al. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic cord injury. Life Sci 2006 79:1895 1905.
61. Shinozaki Y, Sato Y, Koizumi S, Ohno Y, Nagao T, Inoue K. Retinoic acids acting through retinoid receptors protect hippocampal neurons from oxygen-glucose deprivation-mediated cell death by inhibition of c-Jun-N-terminal kinase and p38 mitogen-activated protein kinase. Neuroscience 2007 147:153 163.
62. Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol 2000 20:4699 4707.
63. Collino M, Aragno M, Mastrocola R et al. Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006 530:70 80.
64. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Rec 1999 85:394 402.
65. Desreumaux P, Dubuquoy L, Nutten S et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR) /peroxisome proliferator-activated receptor γ (PPARγ) heterodimer: a basis for new therapeutic strategies. J Exp Med 2001 193:827 838.
66. Bailey ST, Ghosh S. "PPAR"ting ways with inflammation. Nat Immunol 2005 6:966 967.
67. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006 6:44 55.